MedTrace Logo

Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2

NCT04181437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-09-01

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2

Conditions

  • Healthy

Interventions

DRUG

NVP-1203-R1

1 tablet, Single oral dosing

DRUG

NVP-1203-R2

1 tablet, Single oral dosing

DRUG

NVP-1203-R1 and NVP-1203-R2

NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • Yoon Y Ran, M.D. · Kyungpook National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-05-17
Completion
2020-05-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04181437 on ClinicalTrials.gov